Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021,...
Main Authors: | Bacharier, L.B (Author), Bateman, E.D (Author), Boulet, L.-P (Author), Brightling, C.E (Author), Brusselle, G.G (Author), Buhl, R. (Author), Cruz, A.A (Author), Drazen, J.M (Author), Duijts, L. (Author), FitzGerald, J.M (Author), Fleming, L.J (Author), Inoue, H. (Author), Ko, F.W (Author), Krishnan, J.A (Author), Levy, M.L (Author), Lin, J. (Author), Mortimer, K. (Author), Pitrez, P.M (Author), Reddel, H.K (Author), Sheikh, A. (Author), Yorgancioglu, A.A (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
John Wiley and Sons Inc
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Comparing the Efficacy and Influence on the Quality of Life of Three Classes of Drugs Used in Bronchial Asthma - A Prospective Study
by: Ajitha Sharma, et al.
Published: (2014-09-01) -
Comparison of efficacy between long-acting beta 2-agonists (formoterol fumarate) and leukotriene-receptor antagonists (montelukast) as add-on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma
by: Sasikala Kumaravel, et al.
Published: (2014-01-01) -
Some aspects of application of the combination of formoterol and budesonide: what is changed?
by: A. A. Vizel, et al.
Published: (2019-12-01) -
Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
by: Tang B, et al.
Published: (2019-04-01) -
Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate
by: Liang Y, et al.
Published: (2021-02-01)